Bristol-Myers Squibb Company PFD CONV 2
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Stock Overview
Explore Bristol-Myers Squibb Company PFD CONV 2’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
814.6B
P/E Ratio
17.25
EPS (TTM)
$0.23
ROE
0.39%
BMYMP Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 13.31, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $693.12.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 17.25 and a market capitalization of 814.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.